The PROTECT© Trial
Objective: To demonstrate the safety and superior efficacy (10% absolute event rate reduction) of one or two doses of Emisphere SNAC/heparin compared to injectable enoxaparin (Lovenox®) in the prevention of venous thromboembolic events following total hip replacement surgery
Design: Two well-controlled, double-blind, double-dummy studies